Biocon has completed the acquisition of equity shares of Biocon Biologics Limited (BBL) from several entities, including Mylan Inc. Simultaneously, Biocon issued and allotted 17,12,79,553 equity shares to these entities on a preferential basis. The total equity shares acquired from the allottees are 26,19,17,480. This move increases the company’s issued and paid-up equity share capital to Rs. 7,54,12,15,940.
Share Acquisition Completed
Biocon announced the completion of the acquisition of 26,19,17,480 equity shares of Biocon Biologics Limited (BBL) from various entities, collectively referred to as “Allottees.” The acquisition, initially announced on December 06, 2025, was finalized on January 05, 2026.
Details of Allottees and Shares
The allottees from whom the BBL shares were acquired include:
- Mylan Inc.
- Serum Institute Life Sciences Private Limited
- Tata Capital Growth Fund II
- Activ Pine LLP
Equity Share Allotment
Concurrently, Biocon issued and allotted 17,12,79,553 equity shares of the company, with a face value of Rs. 5 each, fully paid-up, on a preferential basis to the Allottees. The issue price was Rs. 405.78 per equity share. These newly allotted shares rank pari-passu with existing equity shares of the company.
Post-Allotment Shareholding
The allotment has resulted in changes to the shareholding structure, with Mylan Inc. now holding 6.10% of the company. The following table details the allotment:
Name of Allottee
Category
No. of BBL equity shares acquired
No. of equity shares allotted by the Company
Post allotment shareholding in the Company
Mylan Inc.
Non-Promoter
14,90,56,984
9,19,67,019
6.10%
Serum Institute Life Sciences Private Limited
–
7,89,02,725
5,54,48,765
3.68%
Tata Capital Growth Fund II
–
88,30,456
62,05,589
0.41%
Activ Pine LLP
–
2,51,27,315
1,76,58,180
1.17%
TOTAL
–
26,19,17,480
17,12,79,553
11.36%
Impact on Share Capital
Following this allotment, the issued, subscribed, and paid-up equity share capital of Biocon has increased from Rs. 6,68,48,18,175 to Rs. 7,54,12,15,940.
Additional Acquisition from Mylan
Biocon also completed the acquisition of 7,18,34,691 equity shares of BBL from Mylan for cash consideration of USD 200 million. Following this, Biocon holds approximately 94% of the paid-up equity share capital of BBL on a fully diluted basis.
Source: BSE
